Home › NDC Lookup › RxCUI directory › RxCUI 858036

Saxagliptin 5 MG Oral Tablet — RxCUI 858036

RxNorm drug concept · Semantic clinical drug
RxCUI 858036 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 19 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI858036
Official nameSaxagliptin 5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assaxagliptin 5 MG (as saxagliptin HCl, anhydrous 5.58 MG) Oral Tablet
FDA products mapped6
Package NDCs mapped19
Reported Medicaid activity (SDUD)4,192 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Saxagliptin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Saxagliptin works by blocking an enzyme called DPP-4, which normally destroys helpful hormones your gut releases after eating. By blocking that enzyme, saxagliptin lets those hormo...
  • What exactly does saxagliptin do — and how is it different from other diabetes pills?
  • You can take saxagliptin with or without food — whichever works best for your routine. A meal does slightly slow down how quickly it's absorbed, but it doesn't meaningfully change...
  • Can I take this pill with food, or do I need to take it on an empty stomach?
📖 Read our full Saxagliptin guide →

🕸️ Concept Web — How Saxagliptin 5 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Saxagliptin 5 MG Oral Tablet RxCUI 858036

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Saxagliptin 857974
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Onglyza 858037
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Saxagliptin Oral Tablet 858035
    • Saxagliptin Oral Product 1158518
    • Saxagliptin Pill 1158519
    • Saxagliptin Oral Tablet [Onglyza] 858039
    • Onglyza Oral Product 1181729
    • Onglyza Pill 1181730
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Saxagliptin 5 MG 858034
    • Saxagliptin 5 MG Oral Tablet [Onglyza] 858040
    • Saxagliptin 5 MG [Onglyza] 858038

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Saxagliptin 5 MG SCDC · 858034
  • Saxagliptin Oral Tablet SCDF · 858035
  • Saxagliptin Oral Product SCDG · 1158518
  • Saxagliptin Pill SCDG · 1158519

Brand-Name Concepts

  • Saxagliptin 5 MG Oral Tablet [Onglyza] SBD · 858040
  • Saxagliptin 5 MG [Onglyza] SBDC · 858038
  • Saxagliptin Oral Tablet [Onglyza] SBDF · 858039
  • Onglyza Oral Product SBDG · 1181729
  • Onglyza Pill SBDG · 1181730
  • Onglyza BN · 858037

📦 FDA Products & Package NDCs

6 products · 19 package NDCs
19 package NDCs map to RxCUI 858036 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-4705-77 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-4705-77) Saxagliptin Mylan Pharmaceuticals Inc. 2023-08-04
00378-4705-93 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-4705-93) Saxagliptin Mylan Pharmaceuticals Inc. 2023-08-04
00378-4706-77 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-4706-77) Saxagliptin Mylan Pharmaceuticals Inc. 2023-08-04
00378-4706-93 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-4706-93) Saxagliptin Mylan Pharmaceuticals Inc. 2023-08-04
65862-0825-01 100 TABLET, FILM COATED in 1 BOTTLE (65862-825-01) Saxagliptin Aurobindo Pharma Limited 2023-07-31
65862-0825-05 500 TABLET, FILM COATED in 1 BOTTLE (65862-825-05) Saxagliptin Aurobindo Pharma Limited 2023-07-31
65862-0825-30 30 TABLET, FILM COATED in 1 BOTTLE (65862-825-30) Saxagliptin Aurobindo Pharma Limited 2023-07-31
65862-0825-90 90 TABLET, FILM COATED in 1 BOTTLE (65862-825-90) Saxagliptin Aurobindo Pharma Limited 2023-07-31
65862-0826-01 100 TABLET, FILM COATED in 1 BOTTLE (65862-826-01) Saxagliptin Aurobindo Pharma Limited 2023-07-31
65862-0826-05 500 TABLET, FILM COATED in 1 BOTTLE (65862-826-05) Saxagliptin Aurobindo Pharma Limited 2023-07-31
65862-0826-30 30 TABLET, FILM COATED in 1 BOTTLE (65862-826-30) Saxagliptin Aurobindo Pharma Limited 2023-07-31
65862-0826-90 90 TABLET, FILM COATED in 1 BOTTLE (65862-826-90) Saxagliptin Aurobindo Pharma Limited 2023-07-31
68462-0726-05 500 TABLET, FILM COATED in 1 BOTTLE (68462-726-05) SAXAGLIPTIN Glenmark Pharmaceuticals Inc., USA 2023-07-31
68462-0726-30 30 TABLET, FILM COATED in 1 BOTTLE (68462-726-30) SAXAGLIPTIN Glenmark Pharmaceuticals Inc., USA 2023-07-31
68462-0726-90 90 TABLET, FILM COATED in 1 BOTTLE (68462-726-90) SAXAGLIPTIN Glenmark Pharmaceuticals Inc., USA 2023-07-31
68462-0727-05 500 TABLET, FILM COATED in 1 BOTTLE (68462-727-05) SAXAGLIPTIN Glenmark Pharmaceuticals Inc., USA 2023-07-31
68462-0727-14 10 BLISTER PACK in 1 CARTON (68462-727-14) / 10 TABLET, FIL... SAXAGLIPTIN Glenmark Pharmaceuticals Inc., USA 2023-07-31
68462-0727-30 30 TABLET, FILM COATED in 1 BOTTLE (68462-727-30) SAXAGLIPTIN Glenmark Pharmaceuticals Inc., USA 2023-07-31
68462-0727-90 90 TABLET, FILM COATED in 1 BOTTLE (68462-727-90) SAXAGLIPTIN Glenmark Pharmaceuticals Inc., USA 2023-07-31
Observed labelers: Aurobindo Pharma Limited (8) · Glenmark Pharmaceuticals Inc., USA (7) · Mylan Pharmaceuticals Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.